Vanguard Global Advisers
TNXP icon

Vanguard Global Advisers’s Tonix Pharmaceuticals TNXP Stock Holding History

Vanguard Global Advisers’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.3K Hold
4,729
– – ﹤0.01% 3001
2026
Q1 		$65K Buy
+4,729
New +$72.8K ﹤0.01% 2907

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Global Advisers's TNXP Position: Q2 2026 in Review

Vanguard Global Advisers held its Tonix Pharmaceuticals (TNXP) position steady in Q2 2026 at 4,729 shares worth $60.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3001.

Vanguard Global Advisers first reported a position in TNXP in Q1 2026 and has held it in 2 quarters since. The position peaked at $65K in Q1 2026. 101 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Vanguard Global Advisers held 4,729 shares of Tonix Pharmaceuticals worth $60.3K as of Q2 2026.
  • Vanguard Global Advisers left its Tonix Pharmaceuticals share count unchanged in Q2 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3001 holding.
  • Vanguard Global Advisers first reported a position in Tonix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Tonix Pharmaceuticals position peaked at $65K in Q1 2026.
  • 101 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.